Document is current
Any future updates will be listed below
-
Authors
Bonolo de Campos, Cecilia http://orcid.org/0000-0003-0383-9533
Meurice, Nathalie
Petit, Joachim L.
Polito, Alysia N.
Zhu, Yuan Xiao
Wang, Panwen
Bruins, Laura A.
Wang, Xuewei
Lopez Armenta, Ilsel D.
Darvish, Susie A.
Ahmann, Greg J.
Henderson, Kimberly J.
Tian, Shulan
Kruse, Jonas J.
Stewart, William M.
Larsen, Jeremy T.
Reeder, Craig B. http://orcid.org/0000-0002-7158-0669
Dingli, David
Kapoor, Prashant
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Fonseca, Rafael
Bergsagel, P. Leif http://orcid.org/0000-0003-1523-7388
Braggio, Esteban
Stewart, A. Keith
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54CA224018)
- License Information
-
More Information
Article History
Received: 31 December 2019
Revised: 3 April 2020
Accepted: 20 April 2020
First Online: 11 May 2020
Conflict of interest
: A.K.S. has a consulting role for Amgen, Bristol-Myers Squibb, Celgene, Ionis, Janssen, Oncopeptides, Ono, Roche, Seattle Genetics, and Takeda and has received research funding from Amgen, Celgene and Janssen. D.D. has a consulting role for Alexion, Janssen, Millenium, and Rigel and has received research funding from Karyopharm. J.L. is declaring advisory board participation for Janssen Oncology and Takeda. P.K. is a principal investigator of clinical trials for which Mayo Clinic receives research funding from Takeda, Janssen, Abbvie, Amgen, GSK and Sanofi, and he has a consulting role with Sanofi and Celgene. R.F. has a consulting role for AbbVie, Amgen, Aduro, Bayer, Bristol-Myers Squibb, Celgene, Kite, Janssen, Juno, Merck, Novartis, Pharmacyclics, Sanofi, and Takeda and is a scientific advisory board member for Adaptive Biotechnologies. S.K. has a consulting role for Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune, Genentech, Amgen, Oncopeptides, and Adaptive and receives research funding for clinical trials to the Institution from Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, AbbVie, Medimmune, Novartis, Roche-Genentech, and Amgen. The remaining authors declare no competing financial interests.
